Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 10, 2026Future Journal of Pharmaceutical SciencesOpen Access

In vitro efficacy of ceftazidime/avibactam and cefiderocol against multidrug-resistant Gram-negative uropathogens: insights into β-lactamase-mediated resistance in clinical isolates

View Full Paper
Ask AI
Bookmark
Share

Authors

MIMohamed A. IbrahimHAHisham A. AbbasGSGhada H. Shaker

Discussion

Loading...

Member takes

Overview

In vitro assessment of ceftazidime/avibactam and cefiderocol against MDR uropathogens highlights urgency for surveillance.

Key Points

  • This study aims to evaluate the efficacy of ceftazidime/avibactam and cefiderocol against multidrug-resistant Gram-negative uropathogens.
  • Included 110 Gram-negative uropathogens identified using biochemical tests.
  • Assessed antimicrobial susceptibility using disk diffusion method.
  • Performed phenotypic and genotypic tests for β-lactamase detection.
  • 80.9% of isolates were multidrug-resistant (MDR).
  • Highest MDR rates were in P. mirabilis (100%) and P. aeruginosa (91%).
  • Ceftazidime/avibactam showed variable activity, with lower susceptibility in K. pneumoniae (83.3%).
  • Cefiderocol had strong activity against CZA- and carbapenem-resistant isolates.

Cite This Study

Ibrahim et al. (2026) studied this question.

synapsesocial.com/papers/69d894526c1944d70ce0539ahttps://doi.org/10.1186/s43094-026-00946-3
View Full Paper
Ask AI
Bookmark
Share